Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1900 1
1949 1
1962 1
1967 1
1973 2
1974 2
1979 1
1980 1
1983 1
1985 1
1986 1
1988 2
1990 1
1992 2
1994 1
1995 1
1997 2
1999 1
2001 2
2002 4
2003 4
2004 1
2005 6
2006 5
2007 4
2008 5
2009 4
2010 3
2011 2
2012 5
2013 4
2014 5
2015 14
2016 11
2017 12
2018 11
2019 13
2020 7
2021 8
2022 5
2023 6
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 28543367

158 results

Results by year

Filters applied: . Clear all
Page 1
Oritavancin: A Long-Half-Life Lipoglycopeptide.
Saravolatz LD, Stein GE. Saravolatz LD, et al. Clin Infect Dis. 2015 Aug 15;61(4):627-32. doi: 10.1093/cid/civ311. Epub 2015 Apr 21. Clin Infect Dis. 2015. PMID: 25900171 Review.
Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
Corey GR, Arhin FF, Wikler MA, Sahm DF, Kreiswirth BN, Mediavilla JR, Good S, Fiset C, Jiang H, Moeck G, Kabler H, Green S, O'Riordan W; SOLO I, SOLO II Investigators. Corey GR, et al. Int J Antimicrob Agents. 2016 Nov;48(5):528-534. doi: 10.1016/j.ijantimicag.2016.07.019. Epub 2016 Sep 13. Int J Antimicrob Agents. 2016. PMID: 27665522 Clinical Trial.
Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, Manos P, Keech R, Singh R, Heller B, Bubnova N, O'Riordan W; SOLO II Investigators. Corey GR, et al. Clin Infect Dis. 2015 Jan 15;60(2):254-62. doi: 10.1093/cid/ciu778. Epub 2014 Oct 6. Clin Infect Dis. 2015. PMID: 25294250 Clinical Trial.
158 results